查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179531

耳鼻喉科治療市場:按藥物類型(抗生素,抗炎,其他),器官(喉嚨,耳,鼻),最終用戶(醫院和診所,家庭護理場所,其他)世界機會分析和行業預測2021-2031

ENT Disorder Treatment Market By Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), By Organ (Throat, Ear, Nose), By End User (Hospital and clinics, Homecare Settings, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 334 Pages | 商品交期: 2-3個工作天內

價格

全球耳鼻喉科治療市場預計 2021 年將達到 237059 萬美元，2031 年將達到 449658 萬美元，2022 年至 2031 年的複合年增長率為 6.5%。

耳朵、鼻子和喉嚨是身體的重要部位。耳朵是負責聽覺和維持全身平衡的感覺器官。鼻子是識別氣味的感覺器官，是抵禦異物侵入的防禦機制，而喉嚨是空氣、水和食物的通道。

由於各種疾病導致這些器官功能障礙，可直接影響生活質量。耳鼻喉疾病的常見類型包括耳部感染、鼻竇感染、扁桃體炎、聽神經瘤和美尼爾氏病。多種藥物用於治療耳鼻喉疾病，包括鼻減充血噴霧劑、口服和局部抗組胺藥、鼻用類固醇和鼻用鹽溶液。此外，各種抗生素可用於治療耳部感染。此外，許多醫療設備也可用於治療老花眼。

推動市場增長的主要因素是環境條件的快速變化、空氣和噪音污染水平的上升以及人口老齡化的加劇。由於免疫系統較差，老年人口更容易被感染，進一步推動了市場增長。例如，根據印度人口預測技術小組發布的一份報告，2021年印度將有約1.38億人超過60歲，預計這一數字在2031年將進一步上升。因此，不斷增長的老年人口正在通過對滴耳劑和抗生素治療鼻子、耳朵和喉嚨感染的需求飆升來推動市場增長。

此外，全球鼻竇炎和慢性鼻炎患病率上升進一步推動了市場增長。此外，發展中國家不斷上升的醫療成本和政府舉措是進一步推動市場增長的主要因素。

然而，醫療設備和鼻竇/扁桃體炎手術的高成本阻礙了市場增長。另一方面，新興醫療保健市場有望在預測期內為市場增長提供有利可圖的機會。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
  • 波特五力分析
  • 大公司定位
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
  • COVID-19 影響分析

4. ENT 治療市場，按藥物類型

  • 概述
    • 市場規模和預測
  • 抗生素藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家分類
  • 抗炎劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

5. 耳鼻喉科治療市場，按器官分類

  • 概述
    • 市場規模/預測
  • 喉
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 耳鼻喉疾病治療市場：按疾病類型
      • 扁桃體炎市場規模和預測：按地區
      • 咽炎市場規模和預測：按地區
      • 扁桃體咽炎市場規模和預測：按地區
      • 其他市場規模/預測：按地區
  • 耳朵
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 耳鼻喉疾病治療市場：按疾病類型
      • 中耳炎市場規模和預測：按地區
      • 外耳炎市場規模轉變和預測：按地區
      • 梅尼埃病的市場規模和預測：按地區
      • 各地區耳鼻咽喉科疾病市場規模及預測
      • 其他市場規模/預測：按地區
  • 鼻子
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 耳鼻喉科鼻病治療市場：按疾病類型
      • 鼻竇炎市場規模和預測：按地區
      • 鼻炎市場規模和預測：按地區
      • 鼻息肉市場規模和預測：按地區
      • 其他市場規模/預測：按地區

6. 最終用戶的耳鼻喉治療市場

  • 概述
    • 市場規模/預測
  • 醫院/診所
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 家庭護理設置
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

7. 按地區劃分的耳鼻喉治療市場

  • 概述
    • 市場規模/預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按藥物類型
    • 北美市場規模和預測：按器官分類
      • 北美喉嚨耳鼻喉疾病治療市場，按疾病類型
      • 北美耳鼻喉疾病治療市場，按疾病類型
      • 北美鼻耳鼻喉疾病治療市場，按疾病類型
    • 北美市場規模和預測：按最終用戶
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按藥物類型
    • 歐洲市場規模和預測：按器官分類
      • 歐洲喉嚨耳鼻喉科治療市場，按疾病類型
      • 歐洲耳鼻喉疾病治療市場：按疾病類型分類
      • 歐洲鼻耳鼻喉疾病治療市場，按疾病類型
    • 歐洲市場規模和預測：按最終用戶
    • 歐洲市場規模和預測：按國家分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 歐洲其他地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和藥物類型預測
    • 亞太市場規模及器官預測
      • 亞太地區喉耳鼻喉疾病治療市場，按疾病類型
      • 亞太地區耳鼻喉疾病治療市場，按疾病類型
      • 亞太地區鼻耳鼻喉疾病治療市場，按疾病類型
    • 亞太耳鼻喉科市場規模和預測：按最終用戶
    • 亞太市場規模和預測：按國家分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 亞太其他地區
  • 拉美亞
    • 主要趨勢和機遇
    • 按藥物類型劃分的 LAMEA 市場規模和預測
    • LAMEA 市場規模和預測：按器官分類
      • LAMEA 喉嚨耳鼻喉疾病治療市場，按疾病類型分類
      • LAMEA 耳鼻喉疾病治療市場，按疾病類型分類
      • LAMEA 鼻耳鼻喉疾病治療市場，按疾病類型分類
    • LAMEA 市場規模和預測：按最終用戶
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非共和國
      • 其餘的 LAMEA

第八章 公司情況

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 競爭熱圖
  • 重大發展

第九章公司簡介

  • Pfizer Inc
  • Teva Pharmaceuticals
  • Novartis
  • Glaxosmithkline plc
  • Bayer Ag
  • Sanofi
  • Amneal Pharmceuticals Ltd
  • Astrazenca Plc
  • Mylan N.V.
  • Akira Healthcare
  • Aurbindo pharma
Product Code: A03484

The global ENT disorder treatment market was valued at $2,370.59 million in 2021, and is projected to reach $4,496.58 million by 2031, registering a CAGR of 6.5% from 2022 to 2031.

Ear, nose and throat are vital parts of the body. Ear is the sensory organ which is responsible to hear sounds, and to maintain the overall balance of the body. Nose is another type of sensory organ which helps to recognize smell; it also works as a defense mechanism restricting the entry of foreign particles, whereas, the throat provides the passage for air, water, and food.

Malfunction in any of these organs due to various diseases can directly affect the quality of life. Some of the common types of ENT disorders are ear-infection, sinus infection, tonsilitis, acoustic neuroma, Meniere's disorder and others. The ENT disorder treatment consists of wide range of drugs such as nasal decongestion sprays, oral and topical anti-histamines, nasal steroids and nasal saline washes. Moreover, to treat ear infection a wide range of antibiotics are available; furthermore, a number of medical devices are also available to cure the presbycusis.

The key factors that drive the growth of market are rapid changes in environmental conditions and the increase in the level of air and noise pollution and rise in geriatric population. As geriatric population is more susceptible to get infected easily due to poor immune system which further propels the growth of the market. For instance, according to the report published by the technical group on population projections for India, about138 million were aged above 60 in India in 2021 and this is further expected to increase in 2031. Thus, increase in the geriatric population surged the demand for ear drops, and antibiotics to treat nasal, ear & throat infection, which drives the growth of the market.

Moreover, rise in the prevalence of sinusitis and chronic rhinitis across the world further drives the growth of market. In addition, rise in healthcare expenditure and increase in government initiatives in developing countries are the key factors that further boost the market growth

However, the high cost of medical devices and for the surgeries for sinusitis and tonsillitis hampers the market growth. Conversely, emerging healthcare market in developing countries is expected to provide the lucrative opportunity for the growth of market during the forecast period. 

The ENT disorder treatment market is segmented on the basis of drug type, organ, end user and region. By drug type it is segmented into antibiotics, anti-inflammatory and others. By organ, it is segmented into ear, nose and throat. By end user the market is segmented into hospitals and clinics, homecare settings and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the ENT disorder treatment market share in 2021 and is anticipated to remain dominant during the forecast period owing to the increase in the healthcare expenditure of this region and presence of major players in the country and the strategies they adopt for their product development.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in the environmental pollution, rise in geriatric population and rise in prevalence of nasal infection, infectious and allergic conditions.

The key players that operate in the ENT disorder treatment market are Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla, AurbindoPharma, Teva Pharmaceuticals, Bayer AG, Amneal Pharmaceuticals Ltd, M.M Pharma, Lyra Therapeutics, Lannet Company Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ent disorder treatment market analysis from 2021 to 2031 to identify the prevailing ent disorder treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the ent disorder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global ent disorder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Antibiotics Drugs
  • Anti Inflammatory Drugs
  • Others

By Organ

  • Throat
    • Disease Type
    • Tonsillitis
    • Pharyngitis
    • Tonsillopharyngitis
    • Others
  • Ear
    • Disease Type
    • Otitis Media
    • Otitis Externa
    • Meniere's Disease
    • Otomycosis
    • Others
  • Nose
    • Disease Type
    • Sinusitis
    • Rhinitis
    • Nasal Polyps
    • Others

By End User

  • Others
  • Hospital and clinics
  • Homecare Settings

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia- Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Pfizer Inc
    • Teva Pharmaceuticals
    • Novartis
    • Glaxosmithkline plc
    • Bayer Ag
    • Sanofi
    • Amneal Pharmceuticals Ltd
    • Astrazenca Plc
    • Mylan N.V.
    • Akira Healthcare
    • Aurbindo pharma

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: ENT DISORDER TREATMENT MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Antibiotics Drugs
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Anti Inflammatory Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: ENT DISORDER TREATMENT MARKET, BY ORGAN

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Throat
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Throat ENT Disorder Treatment Market by Disease Type
      • 5.2.4.1 Tonsillitis Market size and forecast, by region
      • 5.2.4.2 Pharyngitis Market size and forecast, by region
      • 5.2.4.3 Tonsillopharyngitis Market size and forecast, by region
      • 5.2.4.4 Others Market size and forecast, by region
  • 5.3 Ear
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
    • 5.3.4 Ear ENT Disorder Treatment Market by Disease Type
      • 5.3.4.1 Otitis Media Market size and forecast, by region
      • 5.3.4.2 Otitis Externa Market size and forecast, by region
      • 5.3.4.3 Meniere's Disease Market size and forecast, by region
      • 5.3.4.4 Otomycosis Market size and forecast, by region
      • 5.3.4.5 Others Market size and forecast, by region
  • 5.4 Nose
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
    • 5.4.4 Nose ENT Disorder Treatment Market by Disease Type
      • 5.4.4.1 Sinusitis Market size and forecast, by region
      • 5.4.4.2 Rhinitis Market size and forecast, by region
      • 5.4.4.3 Nasal Polyps Market size and forecast, by region
      • 5.4.4.4 Others Market size and forecast, by region

CHAPTER 6: ENT DISORDER TREATMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital and clinics
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Homecare Settings
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: ENT DISORDER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Type
    • 7.2.3 North America Market size and forecast, by Organ
      • 7.2.3.1 North America Throat ENT Disorder Treatment Market by Disease Type
      • 7.2.3.2 North America Ear ENT Disorder Treatment Market by Disease Type
      • 7.2.3.3 North America Nose ENT Disorder Treatment Market by Disease Type
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Type
      • 7.2.5.1.2 Market size and forecast, by Organ
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Type
      • 7.2.5.2.2 Market size and forecast, by Organ
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Type
      • 7.2.5.3.2 Market size and forecast, by Organ
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Type
    • 7.3.3 Europe Market size and forecast, by Organ
      • 7.3.3.1 Europe Throat ENT Disorder Treatment Market by Disease Type
      • 7.3.3.2 Europe Ear ENT Disorder Treatment Market by Disease Type
      • 7.3.3.3 Europe Nose ENT Disorder Treatment Market by Disease Type
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Type
      • 7.3.5.1.2 Market size and forecast, by Organ
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Type
      • 7.3.5.2.2 Market size and forecast, by Organ
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Type
      • 7.3.5.3.2 Market size and forecast, by Organ
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Type
      • 7.3.5.4.2 Market size and forecast, by Organ
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Type
      • 7.3.5.5.2 Market size and forecast, by Organ
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Type
      • 7.3.5.6.2 Market size and forecast, by Organ
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Organ
      • 7.4.3.1 Asia-Pacific Throat ENT Disorder Treatment Market by Disease Type
      • 7.4.3.2 Asia-Pacific Ear ENT Disorder Treatment Market by Disease Type
      • 7.4.3.3 Asia-Pacific Nose ENT Disorder Treatment Market by Disease Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Type
      • 7.4.5.1.2 Market size and forecast, by Organ
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Type
      • 7.4.5.2.2 Market size and forecast, by Organ
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Drug Type
      • 7.4.5.3.2 Market size and forecast, by Organ
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Drug Type
      • 7.4.5.4.2 Market size and forecast, by Organ
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Type
      • 7.4.5.5.2 Market size and forecast, by Organ
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest Of Asia- Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Type
      • 7.4.5.6.2 Market size and forecast, by Organ
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Type
    • 7.5.3 LAMEA Market size and forecast, by Organ
      • 7.5.3.1 LAMEA Throat ENT Disorder Treatment Market by Disease Type
      • 7.5.3.2 LAMEA Ear ENT Disorder Treatment Market by Disease Type
      • 7.5.3.3 LAMEA Nose ENT Disorder Treatment Market by Disease Type
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Type
      • 7.5.5.1.2 Market size and forecast, by Organ
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Type
      • 7.5.5.2.2 Market size and forecast, by Organ
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Type
      • 7.5.5.3.2 Market size and forecast, by Organ
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Type
      • 7.5.5.4.2 Market size and forecast, by Organ
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Pfizer Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Teva Pharmaceuticals
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Novartis
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Glaxosmithkline plc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Bayer Ag
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Sanofi
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Amneal Pharmceuticals Ltd
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Astrazenca Plc
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Mylan N.V.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Akira Healthcare
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Aurbindo pharma
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 2. ENT DISORDER TREATMENT MARKET SIZE, FOR ANTIBIOTICS DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. ENT DISORDER TREATMENT MARKET FOR ANTIBIOTICS DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. ENT DISORDER TREATMENT MARKET SIZE, FOR ANTI INFLAMMATORY DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. ENT DISORDER TREATMENT MARKET FOR ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. ENT DISORDER TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. ENT DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 9. ENT DISORDER TREATMENT MARKET SIZE, FOR THROAT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. ENT DISORDER TREATMENT MARKET FOR THROAT, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 12. ENT DISORDER TREATMENT MARKET, FOR TONSILLITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. ENT DISORDER TREATMENT MARKET, FOR PHARYNGITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. ENT DISORDER TREATMENT MARKET, FOR TONSILLOPHARYNGITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. ENT DISORDER TREATMENT MARKET SIZE, FOR EAR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. ENT DISORDER TREATMENT MARKET FOR EAR, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 19. ENT DISORDER TREATMENT MARKET, FOR OTITIS MEDIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. ENT DISORDER TREATMENT MARKET, FOR OTITIS EXTERNA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. ENT DISORDER TREATMENT MARKET, FOR MENIERE'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. ENT DISORDER TREATMENT MARKET, FOR OTOMYCOSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. ENT DISORDER TREATMENT MARKET SIZE, FOR NOSE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. ENT DISORDER TREATMENT MARKET FOR NOSE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. GLOBAL NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 27. ENT DISORDER TREATMENT MARKET, FOR SINUSITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 28. ENT DISORDER TREATMENT MARKET, FOR RHINITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. ENT DISORDER TREATMENT MARKET, FOR NASAL POLYPS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 30. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. GLOBAL ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 32. ENT DISORDER TREATMENT MARKET SIZE, FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 33. ENT DISORDER TREATMENT MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 34. ENT DISORDER TREATMENT MARKET SIZE, FOR HOMECARE SETTINGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 35. ENT DISORDER TREATMENT MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 36. ENT DISORDER TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 37. ENT DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 38. ENT DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 39. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 40. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 41. NORTH AMERICA THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. NORTH AMERICA EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 43. NORTH AMERICA NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 44. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 45. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 46. U.S. ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 47. U.S. ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 48. U.S. ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. CANADA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 50. CANADA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 51. CANADA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 52. MEXICO ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 53. MEXICO ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 54. MEXICO ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 55. EUROPE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 56. EUROPE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 57. EUROPE THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. EUROPE EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 59. EUROPE NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 60. EUROPE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. EUROPE ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 62. GERMANY ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 63. GERMANY ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 64. GERMANY ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. FRANCE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 66. FRANCE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 67. FRANCE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 68. UK ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 69. UK ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 70. UK ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 71. ITALY ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 72. ITALY ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 73. ITALY ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 74. SPAIN ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 75. SPAIN ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 76. SPAIN ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 78. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 80. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 81. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 87. JAPAN ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 88. JAPAN ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 89. JAPAN ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 90. CHINA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 91. CHINA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 92. CHINA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 94. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 95. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 96. INDIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 97. INDIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 98. INDIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 101. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 102. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 103. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 104. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 105. LAMEA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 106. LAMEA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 107. LAMEA THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 108. LAMEA EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 109. LAMEA NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 110. LAMEA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 111. LAMEA ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 112. BRAZIL ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 113. BRAZIL ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 114. BRAZIL ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 115. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 116. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 117. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 118. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 119. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 120. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 121. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 122. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
  • TABLE 123. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 124.PFIZER INC: COMPANY SNAPSHOT
  • TABLE 125.PFIZER INC: OPERATING SEGMENTS
  • TABLE 126.PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 127.PFIZER INC: NET SALES,
  • TABLE 128.PFIZER INC: KEY STRATERGIES
  • TABLE 129.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 130.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 131.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 132.TEVA PHARMACEUTICALS: NET SALES,
  • TABLE 133.TEVA PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 134.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 135.NOVARTIS: OPERATING SEGMENTS
  • TABLE 136.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 137.NOVARTIS: NET SALES,
  • TABLE 138.NOVARTIS: KEY STRATERGIES
  • TABLE 139.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 140.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 141.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 142.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 143.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 144.BAYER AG: COMPANY SNAPSHOT
  • TABLE 145.BAYER AG: OPERATING SEGMENTS
  • TABLE 146.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 147.BAYER AG: NET SALES,
  • TABLE 148.BAYER AG: KEY STRATERGIES
  • TABLE 149.SANOFI: COMPANY SNAPSHOT
  • TABLE 150.SANOFI: OPERATING SEGMENTS
  • TABLE 151.SANOFI: PRODUCT PORTFOLIO
  • TABLE 152.SANOFI: NET SALES,
  • TABLE 153.SANOFI: KEY STRATERGIES
  • TABLE 154.AMNEAL PHARMCEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 155.AMNEAL PHARMCEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 156.AMNEAL PHARMCEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 157.AMNEAL PHARMCEUTICALS LTD: NET SALES,
  • TABLE 158.AMNEAL PHARMCEUTICALS LTD: KEY STRATERGIES
  • TABLE 159.ASTRAZENCA PLC: COMPANY SNAPSHOT
  • TABLE 160.ASTRAZENCA PLC: OPERATING SEGMENTS
  • TABLE 161.ASTRAZENCA PLC: PRODUCT PORTFOLIO
  • TABLE 162.ASTRAZENCA PLC: NET SALES,
  • TABLE 163.ASTRAZENCA PLC: KEY STRATERGIES
  • TABLE 164.MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 165.MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 166.MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 167.MYLAN N.V.: NET SALES,
  • TABLE 168.MYLAN N.V.: KEY STRATERGIES
  • TABLE 169.AKIRA HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 170.AKIRA HEALTHCARE: OPERATING SEGMENTS
  • TABLE 171.AKIRA HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 172.AKIRA HEALTHCARE: NET SALES,
  • TABLE 173.AKIRA HEALTHCARE: KEY STRATERGIES
  • TABLE 174.AURBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 175.AURBINDO PHARMA: OPERATING SEGMENTS
  • TABLE 176.AURBINDO PHARMA: PRODUCT PORTFOLIO
  • TABLE 177.AURBINDO PHARMA: NET SALES,
  • TABLE 178.AURBINDO PHARMA: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.ENT DISORDER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.ENT DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 3.ENT DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.ENT DISORDER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.ENT DISORDER TREATMENT MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIBIOTICS DRUGS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTI INFLAMMATORY DRUGS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.ENT DISORDER TREATMENT MARKET,BY ORGAN,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF THROAT ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF EAR ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF NOSE ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.ENT DISORDER TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND CLINICS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOMECARE SETTINGS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS ENT DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.ENT DISORDER TREATMENT MARKET BY REGION,2021
  • FIGURE 25.U.S. ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.UK ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SAUDI ARABIA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH AFRICA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA ENT DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.PFIZER INC.: NET SALES ,($MILLION)
  • FIGURE 51.TEVA PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 52.NOVARTIS.: NET SALES ,($MILLION)
  • FIGURE 53.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 54.BAYER AG.: NET SALES ,($MILLION)
  • FIGURE 55.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 56.AMNEAL PHARMCEUTICALS LTD.: NET SALES ,($MILLION)
  • FIGURE 57.ASTRAZENCA PLC.: NET SALES ,($MILLION)
  • FIGURE 58.MYLAN N.V..: NET SALES ,($MILLION)
  • FIGURE 59.AKIRA HEALTHCARE.: NET SALES ,($MILLION)
  • FIGURE 60.AURBINDO PHARMA.: NET SALES ,($MILLION)